Fig. 1

Cholangiocarcinoma harbor frequent DNA repair and chromatin remodeling alterations. A Flowchart of patients and samples characterization. B Clinico-pathological features of patients with CCA. Prior lines of therapy describe the number of treatment lines received prior to sample collection for molecular characterization; iCCA intrahepatic CCA. eCCA extrahepatic CCA. C Oncoplot of mutations detected in tumor biopsies in 128 patients. Significantly mutated genes are listed vertically in decreasing order and hierarchized by functional category. Colored boxes indicate alteration categories observed in each gene and tumor. D Frequency of targetable mutations for OncoKB level 1–4 alterations with a > 5% prevalence. Level 1 = FDA-approved drugs, Level 3 = Clinical Evidence, Level 4 = Biological Evidence. ARID1A status should be updated to level 1–2 according to latest FDA approval of Tulmimetostat. E Somatic interactions plot for the 20 most frequently altered genes. Colored boxes show mutual exclusivity and co-occurring alterations between two genes (*p < 0.05)